Insulet (PODD) has just launched its Omnipod 5 automated insulin delivery system and Omnipod Discover data platform in Spain, expanding its tubeless pump footprint into a 26th country and a 20th Omnipod 5 market.

Insulet’s recent Spain launch comes after a volatile period for the stock, with a 6.11% 7 day share price return and a 5.44% 30 day share price return, in contrast with a year to date share price decline of 42.90% and a 1 year total shareholder return decline of 45.52%. This signals that short term momentum has picked up while longer term performance remains under pressure.

If you are looking beyond Insulet in the medical technology space, this could be a good moment to scan other healthcare focused AI opportunities using the 40 healthcare AI stocks.

After Insulet’s sharp share price setback and modest rebound on the Spain launch, the key issue now is whether current levels still leave meaningful upside ahead or if most of the recovery is already in the rearview mirror.

Most Popular Narrative: 33.4% Undervalued

Insulet’s most followed narrative places fair value at $242.43 per share, well above the recent $161.55 close. This sets up a clear valuation gap built on growth and margin assumptions.

Accelerating penetration of the massive, underpenetrated type 2 diabetes segment, supported by positive pivotal trial data (SECURE-T2D) and improved access/affordability (broad pharmacy distribution, low co-pays), is a new growth engine that significantly increases Insulet's addressable market and sustains ongoing customer base growth, driving durable revenue streams.

Read the complete narrative. Read the complete narrative.

Want to see what kind of revenue expansion and profit uplift need to materialize to support that gap to fair value? The narrative leans on compound growth assumptions, rising profitability, and a future earnings multiple that sits above the wider medical equipment peer group. The full breakdown brings these moving parts together into one pricing story.

Result: Fair Value of $242.43 (UNDERVALUED)

However, Insulet’s heavy dependence on the Omnipod platform and rising competition in insulin pumps could pressure growth expectations and challenge the bullish narrative if execution stumbles.

Another View on Insulet’s Valuation

While the most popular Insulet narrative leans on a future earnings path and target P/E to argue the stock is undervalued, the current P/E of 37x tells a different story. That multiple sits above both the US Medical Equipment industry at 26.8x and an estimated fair ratio of 32x. This points to material valuation risk if sentiment cools or execution wobbles.

In practical terms, you are paying more for each dollar of Insulet earnings today than both peers and the fair ratio suggest. The key question is whether you are comfortable underwriting that richer tag while the Omnipod story plays out or prefer to wait for a cheaper entry point, if it comes.

Next Steps

Plenty of opinions are already forming around Insulet, but the real edge comes from testing those views against the numbers yourself and moving early. To see how the balance of concerns and potential rewards stacks up, start with the 2 key rewards and 1 important warning sign.

Looking For More Investment Ideas Beyond Insulet?

If Insulet has sharpened your interest, do not stop here. Broaden your watchlist using targeted screeners that surface stocks with specific strengths and clearer risk profiles.

• Pinpoint potential value opportunities by scanning companies that appear attractively priced on quality and fundamentals using the 45 high quality undervalued stocks.
• Strengthen your focus on resilience by zeroing in on businesses highlighted in the 74 resilient stocks with low risk scores.
• Spot early stage opportunities with solid underpinnings by reviewing the screener containing 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.